Answers are grounded in this paper and cite their sources.
Guilu Erxian Jiao (GEJ) is a widely used herbal product for anti-aging and treatment of degenerative joint diseases. As drug adverse events of GEJ have not been well established, this paper was designed to assess adverse events of GEJ. 96 healthy volunteers were enrolled in this study, and a randomized, placebo-controlled, double-blind clinical trial was conducted. Adherence-to-protocol design was adopted to assess the precise side effects. Analysis on laboratory data of renal function, liver function, hematological changes, immunological parameters and questionnaires about possible adverse effects after two-month medical treatment were performed. In addition, another self-report of adverse events after taking GEJ was recorded. There were no clinically significant changes of biochemical indicators of liver function, renal function and hemogram. Ratio of CD4(superscript +) to CD8(superscript +) lymphocyte counts reversed in the subgroup of higher GEJ dosage (300mg/day and 450mg/day) which may explain the effectiveness of GEJ for osteoarthritis. In the analysis of the questionnaire, mouth dryness was the only one adverse event and its severity seemed not relevant to GEJ dosage. Further clinical trials can be designed based on the safety profile to evaluate the effectiveness of GEJ.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: